TY - JOUR T1 - Prevention of type 2 diabetes—where do you draw the line? JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 37 LP - 37 DO - 10.1136/dtb.2017.4.0464 VL - 55 IS - 4 A2 - , Y1 - 2017/04/01 UR - http://dtb.bmj.com/content/55/4/37.abstract N2 - Choosing a pharmacological management strategy for people with type 2 diabetes is controversial because much of the evidence for therapeutic interventions relies on surrogate outcomes.1 Recently however, the way that pre-diabetes is identified has been challenged,2 possibly undermining an NHS England programme to reduce the health burden of the disease.3 At the heart of this lies a debate over the meaning and utility of terms such as non-diabetic hyperglycaemia and pre-diabetes, and unanswered questions over the place of drug treatment.4Healthier you: the NHS Diabetes Prevention Programme was announced in 2015 with the aim of significantly reducing or delaying the … ER -